Venous thromboembolism prevention and treatment with factor XI/XIa inhibitors: current status and future perspectives
Research article published in Journal of thrombosis and thrombolysis (2026)
Abstract
Current treatments for venous thromboembolism include warfarin, various heparins, and direct oral anticoagulants. While effective, there's ongoing research for safer alternatives, especially for high-risk patients (e.g., cancer, post-operative, and those with end-stage renal disease). Factor XI has been identified as crucial in abnormal thrombosis but less so in normal hemostasis, suggesting that inhibiting it could reduce thrombosis while also limiting bleeding risks. Recent phase 2 trials on factor XI inhibitors show promise for preventing venous thromboembolism in patients undergoing total knee arthroplasty, in cancer patients, and in patients with end-stage renal disease. Three key unmet needs include: need for large-scale phase 3 clinical trials, broader surgical applications and management of bleeding complications/reversal strategies. Further research on these aspects is essential, especially as factor XI inhibitors progress towards clinical use.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Peer-reviewed research on anticoagulant and antithrombotic drug development relevant to leech-derived therapeutics. Indexed in PubMed and verified against the NCBI record.
Why This Matters for Hirudotherapy
This review examines Factor XI/XIa inhibitors for venous thromboembolism (VTE), summarizing phase 2 data suggesting promise in total knee arthroplasty, cancer, and end-stage renal disease patients, and flagging three unmet needs: large phase 3 trials, broader surgical applications, and bleeding-reversal strategies. For the medicinal-leech secretome drug-discovery narrative it is supportive context — it shows continued momentum toward anticoagulants that suppress pathological thrombosis while sparing normal hemostasis, the same selectivity principle that makes leech-derived antithrombotic proteins of scientific interest as natural-product leads. The caveat is that this is a review of synthetic/biologic FXI agents still largely in phase 2 development, with no leech involvement and no completed phase 3 outcomes, so it informs the broader anticoagulation landscape rather than hirudotherapy directly.
Citation
Venous thromboembolism prevention and treatment with factor XI/XIa inhibitors: current status and future perspectives.
Del et al. · Journal of thrombosis and thrombolysis, 2026
Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026